Metabolic Associated Fatty Liver DiseaseNCT04871880
Lifestyle Modification for MAFLD Based on TTM
A study testing Dietitian led life style modification intervention in people with Metabolic Associated Fatty Liver Disease, run by Nanfang Hospital, Southern Medical University at 1 site in China.
Trial summary
Lifestyle changes aiming at weight loss remain the cornerstone of MAFLD treatment.Evaluating the motivational stage of patients' change and providing targeted lifestyle guidance may significantly improve the efficiency of weight loss. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Metabolic Associated Fatty Liver Disease
- What is being tested?
- Dietitian led life style modification intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 75 participants
- Where
- 1 siteChina
- Study dates
- 17 May 2020to 30 Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- With age range of 18-65 years.
- BMI ≥ 28kg/m2
- Fatty infiltration of the liver was confirmed on imaging studies (ultrasound, transient elastography, computed tomography, or magnetic resonance imaging) or liver biopsy.
- With valid motivational stage assessment based on TTM.
- Written consent form obtained.
Who cannot join
- History of other chronic liver disease (Viral hepatitis B or C, autoimmune hepatitis, cholestatic and Inherited metabolic liver diseases) and hemochromatosis.
- Self-reported HIV-positive status, active tuberculosis, active malaria, or inflammatory bowel disease.
- Excessive alcohol consumption (>30g/d for men and >20g/d for women).
- Patient has known cirrhosis (compensated/decompensated) either based on clinical criteria or liver histology or Imaging techniques.
- Subjects using thyroid hormones, oestrogens, amiodarone, steroids, tamoxifen and other medicine known to affect liver fat accumulation.
- Subjects using thiazolidinedione hypoglycemic drugs, vitamin E and other medicine have potential benefits for NASH within six months.
Show all 18Show fewer
- Subjects with organ failure.
- Subjects with hepatocellular carcinoma or other active malignancy.
- Solid organ transplant recipients.
- Antibiotic treatment within the previous 3 months.
- Suffering from any acute or chronic cardiovascular, GI or immunological condition.
- Gastric or duodenal ulcer in the past six months.
- Currently pregnant or nursing.
- Concomitant diseases with reduced life expectancy.
- Combined mental illness.
- Contraindication to MRI scanning.
- Exclusions may also be made at the discretion of the attending physician or the eligibility committee.
- Inability to provide informed consent.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong
Jinjun Chen, 86-18588531001, chjj@smu.edu.cn
Ling Zhou, 86-13631383539, vzhouling3168@163.com
About this study
Official title: Lifestyle Modification for the Treatment of Metabolic Associated Fatty Liver Disease Based on Transtheoretical Model: a Single-center, Randomized, Controlled Study
Lifestyle changes aiming at weight loss remain the cornerstone of MAFLD treatment.Evaluating the motivational stage of patients' change and providing targeted lifestyle guidance may significantly improve the efficiency of weight loss. The investigators hypothesize that gut microbiota may affect motivation to lose weight, and the changes in gut microbiota due to weight loss may positively feedback the behavior of motivation, forming a virtuous circle. Thus, this study aims at ①evaluating the relationships between motivational stage of weight loss and the gut microbiota (Gut-brain axis); ②investigating the effects of lifestyle interventions on the gut microbiota in MAFLD patients.
Read the detailed description
Fatty liver associated with metabolic dysfunction is common, affects a quarter of the population, and has no approved drug therapy. In 2020, two position articles have proposed not only the change of the terminology from NAFLD to metabolic associated fatty liver disease (MAFLD), but also an update and revision of the definition of fatty liver disease. According to these papers, indeed, the diagnosis of MAFLD can be made with the presence of hepatic steatosis (detected by serum biomarker scores, imaging methods or histology) and at least one of the fol- lowing metabolic criteria: (a) overweight/obesity, (b) T2DM and (c) metabolic dysregulation (that means at least two factors among increased waist circumference, hypertension, hypertriglyceridemia, low serum HDL-cholesterol levels, impaired fasting glucose, homeostatic model assessment of insulin resistance [HOMA-IR] > 2.5 or high sensitivity C-reactive protein > 2 mg/L). Here,the investigators focus on the obese NAFLD, which considered as a sub-phenotype in MAFLD.
Lifestyle changes aiming at weight loss remain the cornerstone of MAFLD treatment. However, it is not easy to make patients change their unhealthy lifestyle. Behavior therapy may only be successful in motivated patients, and motivation to dieting and exercising may be different according to age and sex. Personal motivation for change plays a pivotal role in behavior changes. The transtheoretical model (TTM) is an empirically validated model of individual behavioral change, which involves progress through a series of stages to make a particular behavioral change. TTM-based interventions have been applied to facilitate health behavioral changes, such as physical exercise, smoking cessation, and weight management, studies of which continue to demonstrate positive effects. Evaluating the motivational stage of patients' change and providing targeted lifestyle guidance may significantly improve the efficiency of weight loss. The investigators hypothesize that gut microbiota may affect motivation to lose weight, and the changes in gut microbiota due to weight loss may positively feedback the behavior of motivation, forming a virtuous circle.
Thus, a total of seventy obese patients with NAFLD will be recruited in this study, divided into lifestyle modification program group(n=35) and usual care group(n=35). All subjects will undergo dietary assessment based on Food Frequency Questionnaire ( FFQ) and motivational stages evaluation based on TTM. Stool samples will be collected at each visit. Demographic data will be recorded, consisted of age, weight, height, waist circumference, BMI, and so on. MRI-PDFF will be performed to evaluate liver steatosis. Meanwhile, vibration-controlled transient elastography will be carried out, which include liver stiffness (LSM) and controlled attenuation parameter (CAP) measurements. Biochemistry tests will be conducted as supplementary for assessment of NAFLD and cardiovascular risks, comprising liver function test, lipid, fasting glucose, etc.
The investigators aim at ①evaluating the relationships between motivational stage of weight loss and the gut microbiota (Gut-brain axis); ②investigating the effects of lifestyle interventions on the gut microbiota in MAFLD patients.
- Conditions
- Metabolic Associated Fatty Liver Disease
- Being tested
- Dietitian led life style modification intervention, Conventional care (control)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dietitian led life style modification interventionBehavioural
All participants received recommendations for a low-fat hypocaloric diet that was 750 kcal/day less than their daily energy need which supervised by dietitians. Additionally, patients were encouraged to walk 200 minutes per weeks and a short self-report questionnaire for the measurement of habitual physical activity was implemented at baseline, 4, 16, 32 and 48 weeks.
Conventional care (control)Behavioural
Receive routine care
| Study group | Role | What they receive |
|---|---|---|
| Dietitian led life style modification intervention. | Experimental | Lifestyle changes supervised by dietitians Receives: Behavioral: Dietitian led life style modification intervention |
| Conventional care (control) | Experimental | Receive routine care Receives: Behavioral: Conventional care (control) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hepatic fat
Change of liver proton density fat fraction (PDFF) in MAFLD assessed by magnetic resonance imaging (MRI)
Measured: 12 months
Obesity
Changes in body weight
Measured: 1, 4, 8, 12, 24 months
Gut microbiota
Changes in bacterial component of the gut microbiome
Measured: 1, 4, 8, 12, 24 months
Secondary outcomes (9)
Blood pressure
Changes in blood pressure
Measured: 1, 4, 8, 12, 24 months
Central obesity
Changes in waist circumference
Measured: 1, 4, 8, 12, 24 months
Insulin resistance
Changes in insulin resistance eveluated by HOMA-IR
Measured: 1, 4, 8, 12, 24 months
FPG
Changes in fast plasma glucose
Measured: 1, 4, 8, 12, 24 months
HbA1c
Changes in HbA1c
Measured: 1, 4, 8, 12, 24 months
Plasma triglycerides
Changes in plasma triglycerides
Measured: 1, 4, 8, 12, 24 months
Plasma HDL-cholesterol
Changes in plasma HDL-cholesterol
Measured: 1, 4, 8, 12, 24 months
Plasma high-sensitivity C-reactive protein level
Changes in plasma high-sensitivity C-reactive protein level
Measured: 1, 4, 8, 12, 24 months
Gut microbiota diversity
Changes in diversity of gut microbiome(α-diversity and β-diversity)
Measured: 1, 4, 8, 12, 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 May 2021
- Study start17 May 2020
- Primary completion17 May 2024 (estimated)
- Study completion30 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Metabolic Associated Fatty Liver DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 75 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Nanfang Hospital, Southern Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04871880
- Sponsor's protocol ID
- NFEC-2019-254
- Status last verified
- Apr 2021
- First submitted
- 20 Apr 2021
- Last updated
- 4 May 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 4 May 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Lifestyle Modification for the Treatment of Metabolic Associated Fatty Liver Disease Based on Transtheoretical Model: a Single-center, Randomized, Controlled Study
- ClinicalTrials.gov ID
- NCT04871880
- Acronym / sponsor ID
- NFEC-2019-254
- Conditions
- Metabolic Associated Fatty Liver Disease
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 75 participants (estimated)
- Lead sponsor
- Nanfang Hospital, Southern Medical UniversityUniversity, hospital or other
- Study start
- 17 May 2020 (actual)
- Primary completion
- 17 May 2024 (estimated)
- Study completion
- 30 Dec 2024 (estimated)
- First posted
- 4 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Lifestyle changes aiming at weight loss remain the cornerstone of MAFLD treatment.Evaluating the motivational stage of patients' change and providing targeted lifestyle guidance may significantly improve the efficiency of weight loss. The investigators hypothesize that gut microbiota may affect motivation to lose weight, and the changes in gut microbiota due to weight loss may positively feedback the behavior of motivation, forming a virtuous circle. Thus, this study aims at ①evaluating the relationships between motivational stage of weight loss and the gut microbiota (Gut-brain axis); ②investigating the effects of lifestyle interventions on the gut microbiota in MAFLD patients.
Detailed description
Fatty liver associated with metabolic dysfunction is common, affects a quarter of the population, and has no approved drug therapy. In 2020, two position articles have proposed not only the change of the terminology from NAFLD to metabolic associated fatty liver disease (MAFLD), but also an update and revision of the definition of fatty liver disease. According to these papers, indeed, the diagnosis of MAFLD can be made with the presence of hepatic steatosis (detected by serum biomarker scores, imaging methods or histology) and at least one of the fol- lowing metabolic criteria: (a) overweight/obesity, (b) T2DM and (c) metabolic dysregulation (that means at least two factors among increased waist circumference, hypertension, hypertriglyceridemia, low serum HDL-cholesterol levels, impaired fasting glucose, homeostatic model assessment of insulin resistance [HOMA-IR] > 2.5 or high sensitivity C-reactive protein > 2 mg/L). Here,the investigators focus on the obese NAFLD, which considered as a sub-phenotype in MAFLD.
Lifestyle changes aiming at weight loss remain the cornerstone of MAFLD treatment. However, it is not easy to make patients change their unhealthy lifestyle. Behavior therapy may only be successful in motivated patients, and motivation to dieting and exercising may be different according to age and sex. Personal motivation for change plays a pivotal role in behavior changes. The transtheoretical model (TTM) is an empirically validated model of individual behavioral change, which involves progress through a series of stages to make a particular behavioral change. TTM-based interventions have been applied to facilitate health behavioral changes, such as physical exercise, smoking cessation, and weight management, studies of which continue to demonstrate positive effects. Evaluating the motivational stage of patients' change and providing targeted lifestyle guidance may significantly improve the efficiency of weight loss. The investigators hypothesize that gut microbiota may affect motivation to lose weight, and the changes in gut microbiota due to weight loss may positively feedback the behavior of motivation, forming a virtuous circle.
Thus, a total of seventy obese patients with NAFLD will be recruited in this study, divided into lifestyle modification program group(n=35) and usual care group(n=35). All subjects will undergo dietary assessment based on Food Frequency Questionnaire ( FFQ) and motivational stages evaluation based on TTM. Stool samples will be collected at each visit. Demographic data will be recorded, consisted of age, weight, height, waist circumference, BMI, and so on. MRI-PDFF will be performed to evaluate liver steatosis. Meanwhile, vibration-controlled transient elastography will be carried out, which include liver stiffness (LSM) and controlled attenuation parameter (CAP) measurements. Biochemistry tests will be conducted as supplementary for assessment of NAFLD and cardiovascular risks, comprising liver function test, lipid, fasting glucose, etc.
The investigators aim at ①evaluating the relationships between motivational stage of weight loss and the gut microbiota (Gut-brain axis); ②investigating the effects of lifestyle interventions on the gut microbiota in MAFLD patients.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Dietitian led life style modification intervention. | Experimental | Behavioral: Dietitian led life style modification interventionLifestyle changes supervised by dietitians |
| Conventional care (control) | Experimental | Behavioral: Conventional care (control)Receive routine care |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- With age range of 18-65 years.
- BMI ≥ 28kg/m2
- Fatty infiltration of the liver was confirmed on imaging studies (ultrasound, transient elastography, computed tomography, or magnetic resonance imaging) or liver biopsy.
- With valid motivational stage assessment based on TTM.
- Written consent form obtained.
Key exclusion criteria (18 listed)
- History of other chronic liver disease (Viral hepatitis B or C, autoimmune hepatitis, cholestatic and Inherited metabolic liver diseases) and hemochromatosis.
- Self-reported HIV-positive status, active tuberculosis, active malaria, or inflammatory bowel disease.
- Excessive alcohol consumption (>30g/d for men and >20g/d for women).
- Patient has known cirrhosis (compensated/decompensated) either based on clinical criteria or liver histology or Imaging techniques.
- Subjects using thyroid hormones, oestrogens, amiodarone, steroids, tamoxifen and other medicine known to affect liver fat accumulation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dietitian led life style modification interventionAll participants received recommendations for a low-fat hypocaloric diet that was 750 kcal/day less than their daily energy need which supervised by dietitians. Additionally, patients were encouraged to walk 200 minutes per weeks and a short self-report questionnaire for the measurement of habitual physical activity was implemented at baseline, 4, 16, 32 and 48 weeks. | Behavioural | Dietitian led life style modification intervention. |
| Conventional care (control)Receive routine care | Behavioural | Conventional care (control) |
Primary outcome
Hepatic fat
Time frame: 12 months
Change of liver proton density fat fraction (PDFF) in MAFLD assessed by magnetic resonance imaging (MRI)
Obesity
Time frame: 1, 4, 8, 12, 24 months
Changes in body weight
Gut microbiota
Time frame: 1, 4, 8, 12, 24 months
Changes in bacterial component of the gut microbiome
9 secondary outcomes
Blood pressure
Time frame: 1, 4, 8, 12, 24 months
Central obesity
Time frame: 1, 4, 8, 12, 24 months
Insulin resistance
Time frame: 1, 4, 8, 12, 24 months
FPG
Time frame: 1, 4, 8, 12, 24 months
HbA1c
Time frame: 1, 4, 8, 12, 24 months
Plasma triglycerides
Time frame: 1, 4, 8, 12, 24 months
Plasma HDL-cholesterol
Time frame: 1, 4, 8, 12, 24 months
Plasma high-sensitivity C-reactive protein level
Time frame: 1, 4, 8, 12, 24 months
Gut microbiota diversity
Time frame: 1, 4, 8, 12, 24 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 May 2021.
- Individual participant dataSharing planned: Undecided
Related trials for Metabolic Associated Fatty Liver Disease
Recruiting
Dietary Glycine Supplementation in Metabolic Dysfunction-associated Steatotic Liver Disease
Metabolic Dysfunction Associated Fatty Liver Disease
RecruitingPhase 2
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
RecruitingObservational study
Evaluation of Non-Invasive Tests for Metabolic Liver Disease
Metabolic Associated Fatty Liver Disease, Metabolic Associated Steatotic Liver Disease
Recruiting
Exercise for an Aging Liver (EXALIVER)
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Not yet recruitingPhase 4
Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance
MAFLD in Prediabetes and Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dietitian led life style modification intervention in people with Metabolic Associated Fatty Liver Disease, run by Nanfang Hospital, Southern Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 4 May 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Jinjun Chen (8618588531001, chjj@smu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hepatic fat (time frame: 12 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2021.